Transcriptional activation of PD-L1 by Sox2 contributes to the proliferation of hepatocellular carcinoma cells

Oncology Reports

Volumn 37, Issue 5, 2017, Pages 3061-3067

  Zhong, Feng ^a   Cheng, Xinsheng ^b   Sun, Shibo ^a   Zhou, Jie ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b Affiliated Shenzhen Sixth Hospital of Guangdong Medical University   (China)

Author keywords

Hepatocellular carcinoma; PD L1; Sox2

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; TRANSCRIPTION FACTOR SOX2; CD274 PROTEIN, HUMAN; SOX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX;

APOPTOSIS; ARTICLE; BINDING SITE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; EPITHELIAL MESENCHYMAL TRANSITION; GEL MOBILITY SHIFT ASSAY; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; OVERALL SURVIVAL; PLASMID; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN MOTIF; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; RNA EXTRACTION; RNA INTERFERENCE; TRANSCRIPTION INITIATION; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; HEP-G2 CELL LINE; LIVER TUMOR; METABOLISM; TUMOR CELL LINE; UPREGULATION;

ANTIGENS, CD274; APOPTOSIS; BINDING SITES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; PROMOTER REGIONS, GENETIC; SOXB1 TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 85018630883     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2017.5523     Document Type: Article

References (38)

1. Farazi PA and DePinho RA: Hepatocellular carcinoma pathogenesis: From genes to environment. Nat Rev Cancer 6: 674-687, 2006.
2. Simonetti RG, Liberati A, Angiolini C and Pagliaro L: Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials. Ann Oncol 8: 117-136, 1997
3. Mas VR, Fisher RA, Archer K.J., Yanek KC, Williams B, Dumur CI and Maluf DG: Genes associated with progression and recurrence of hepatocellular carcinoma in hepatitis C patients waiting and undergoing liver transplantation: Preliminary results. Transplantation 83: 973-981, 2007.
4. Moradpour D and Blum HE: Pathogenesis of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 17: 477-483, 2005.
5. Nam SW, Park JY, Ramasamy A, Shevade S., Islam A, Long PM, Park C.K., Park SE, Kim SY, Lee SH, et al: Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology 42: 809-818, 2005.
6. Poon TC, Wong N, Lai P.B., Rattray M., Johnson PJ and Sung JJ: A tumor progression model for hepatocellular carcinoma: Bioinformatic analysis of genomic data. Gastroenterology 131: 1262-1270, 2006.
7. Teufel A, Staib F, Kanzler S., Weinmann A, Schulze-Bergkamen H and Galle PR: Genetics of hepatocellular carcinoma. World J Gastroenterol 13: 2271-2282, 2007
8. Schäfer DF and Sorrell MF: Hepatocellular carcinoma. Lancet 353: 1253-1257, 1999
9. Mas VR, Maluf DG, Archer K.J., Yanek K., Kong X, Kulik L, Frei se CE, Olthoff KM, Ghobrial RM, Mclver P, et al: Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma. Mol Med 15: 85-94, 2009
10. Rodda DJ, Chew JL, Lim L.H., Loh Y H, Wang B, Ng HH and Robson P: Transcriptional regulation of nanog by OCT4 and SOX2. J Biol Chem 280: 24731-24737, 2005
11. Bass AJ, Watanabe H, Mermel C.H., Yu S., Perner S, Verhaak RG, Kim S.Y., Wardwell L., Tamayo P, Gat-Viks I, et al: SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 41: 1238-1242, 2009
12. Chen Y, Shi L, Zhang L., Li R, Liang J, Yu W., Sun L, Yang X, Wang Y., Zhang Y, et al: The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem 283: 17969-17978, 2008.
13. Hussenet T, Dali S, Exinger J., Monga B, Jost B, Dembelé D, Martinet N, Thibault C, Huelsken J, Brambilla E, et al: SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One 5: e8960, 2010.
14. Hussenet T and du Manoir S: SOX2 in squamous cell carcinoma: Amplifying a pleiotropic oncogene along carcinogenesis. Cell Cycle 9: 1480-1486, 2010.
15. Justilien V, Walsh MP, Ali S.A., Thompson EA, Murray NR and Fields AP: The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma. Cancer Cell 25: 139-151, 2014
16. Schoenhals M, Kassambara A, De Vos J, Hose D, Moreaux J and Klein B: Embryonic stem cell markers expression in cancers. Biochem Biophys Res Commun 383: 157-162, 2009
17. Huang P, Qiu J, Li B., Hong J, Lu C, Wang L., Wang J, Hu Y, Jia W and Yuan Y Role of Sox2 and Oct4 in predicting survival of hepatocellular carcinoma patients after hepatectomy. Clin Biochem 44: 582-589, 2011.
18. Sun C, Sun L, Li Y., Kang X, Zhang S and Liu Y Sox2 expression predicts poor survival of hepatocellular carcinoma patients and it promotes liver cancer cell invasion by activating Slug. Med Oncol 30: 503, 2013.
19. Zhao C, Li Y, Zhang M., Yang Y and Chang L MIR-126 inhibits cell proliferation and induces cell apoptosis of hepatocellular carcinoma cells partially by targeting Sox2. Hum Cell 28: 91-99, 2015
20. Blank C, Kuball J, Voelkl S., Wiendl H, Becker B, Walter B., Majdic O, Gajewski TF, Theobald M, Andreesen R., et al: Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 119: 317-327, 2006.
21. Herbst RS, Soria JC, Kowanetz M, Fine G.D., Hamid O., Gordon MS, Sosman JA, McDermott DF, Powderly J.D., Gettinger SN, et al: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515: 563-567, 2014
22. Zeng Z, Shi F, Zhou L., Zhang MN, Chen Y, Chang XJ, Lu Y.Y., Bai WL, Qu JH, Wang CP, et al: Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. PLoS One 6: e23621, 2011.
23. Nomi T, Sho M, Akahori T., Hamada K, Kubo A, Kanehiro H., Nakamura S, Enomoto K, Yagita H., Azuma M, et al: Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 13: 2151-2157, 2007
24. Butte MJ, Keir ME, Phamduy T.B., Sharpe AH and Freeman GJ: Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27: 111-122, 2007
25. Park JJ, Omiya R, Matsumura Y., Sakoda Y, Kuramasu A, Augustine M.M., Yao S., Tsushima F, Narazaki H, Anand S., et al: B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood 116: 1291-1298, 2010.
26. Paterson AM, Brown KE, Keir M.E., Vanguri VK, Riella LV, Chandraker A, Sayegh M.H., Blazar BR, Freeman GJ and Sharpe AH: The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol 187: 1097-1105, 2011.
27. Motzer RJ, Rini BI, McDermott D.F., Redman BG, Kuzel TM, Harrison MR, Vaishampayan U.N., Drabkin HA, George S, Logan TF, et al: Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 33: 1430-1437, 2015
28. Robert C, Ribas A, Wolchok J.D., Hodi FS, Hamid O, Kefford R, Weber J.S., Joshua AM, Hwu WJ, Gangadhar TC, et al: Antiprogrammed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 384: 1109-1117, 2014
29. Gao Q, Wang XY, Qiu S.J., Yamato I., Sho M, Nakajima Y, Zhou J., Li BZ, Shi YH, Xiao YS, et al: Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 15: 971-979, 2009
30. Li Y, Wang H, Wang X., Jin W, Tan Y, Fang H., Chen S, Chen Z and Wang K Genome-wide studies identify a novel interplay between AML1 and AML1/ETO in t(8;21) acute myeloid leukemia. Blood 127: 233-242, 2016.
31. Matys V, Kel-Margoulis OV, Fricke E., Liebich I, Land S, Barre-Dirrie A, Reuter I., Chekmenev D, Krull M, Hornischer K., et al: TRANSFAC and its module TRANSCompel: Transcriptional gene regulation in eukaryotes. Nucleic Acids Res 34: D108-D110, 2006.
32. Lin R, Maeda S, Liu C., Karin M and Edgington TS: A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene 26: 851-858, 2007
33. Sakamoto M: Early HCC: Diagnosis and molecular markers. J Gastroenterol 44 (Suppl 19): 108-111, 2009
34. Xu X, Liu RF, Zhang X, Huang L.Y., Chen F., Fei QL and Han ZG: DLK1 as a potential target against cancer stem/progenitor cells of hepatocellular carcinoma. Mol Cancer Ther 11: 629-638, 2012.
35. Shi F, Shi M, Zeng Z., Qi RZ, Liu ZW, Zhang JY, Yang Y.P., Tien P and Wang FS: PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 128: 887-896, 2011.
36. Pan X, Cang X, Dan S., Li J, Cheng J, Kang B., Duan X, Shen B and Wang YJ: Site-specific disruption of the Oct4/Sox2 protein interaction reveals coordinated mesendodermal differentiation and the epithelial-mesenchymal transition. J Biol Chem 291: 18353-18369, 2016.
37. Scaffidi P and Bianchi ME: Spatially precise DNA bending is an essential activity of the sox2 transcription factor. J Biol Chem 276: 47296-47302, 2001.
38. Wu C, Zhu Y, Jiang J., Zhao J, Zhang XG and Xu N: Immuno-histochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 108: 19-24, 2006.